Natural Killer Cells Convergence Research Team - Stand Up To Cancer

Convergence Teams

Research  >  Research Portfolio  >  Convergence Teams  >  Natural Killer Cells Convergence Research Team

SU2C Natural Killer Cells Convergence Research Team: Integrating Experimental and Computational Pipelines to Develop Biomarkers of Tumor Cell Resistance to NK Cells

Grant Term: January 2018–December 2020

This SU2C Natural Killer Cells Convergence Research Team is conducting an in-depth study of natural killer (NK) cells and their anticancer properties using a CRISPR screen, sophisticated bioinformatics, and high-tech culture techniques. The team is engaging computational teams with follow-up in a clinical setting to model bone marrow living tissue scaffolds with humanized stromal tissue.


Natural killer (NK) cells, white blood cells that play a role in viral response, have potent antitumor properties. Moreover, NK cells are not inhibited by many of the strategies cancer cells use to evade the immune system. This SU2C Natural Killer Cells Convergence Research Team hypothesizes that the genetic makeup of a tumor may serve as a basis for targeting its destruction by NK cells.

To identify biomarkers that indicate tumor cell sensitivity or resistance to NK cells, the team is using computational approaches. Team members are also exploring novel ways in which NK cells affect tumor cells by using tools such as CRISPR screens. They are also validating these biomarkers on different experimental platforms, such as patient-derived organoids and high-throughput systems to quantify tumor cell responses to immune effector cells.

Results from this research could impact models used to develop therapies for a wide range of cancers.


Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.